Lucentis (ranibizumab) faces oncoming competition from 4 companies that are developing proposed biosimilars.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.